
ÃֽŠÄÜÅÃÆ®·»Áî ÀÓ»óÇÐ
- ÀúÀÚ(±Û)Çѱ¹ÄÜÅÃÆ®·»ÁîÇÐȸ
- ÃâÆÇ»ç±ºÀÚÃâÆÇ»ç
- ¹ßÇàÀÏ2015³â
°¢¸· ÀÌÁ¾ÀÌ½Ä ¿¬±¸ Ȱ¹ß
ÁÖ¿ä Áø·á ºÐ¾ß´Â ¹é³»Àå, °¢¸·À̽Ä, °Ç¼º¾È, ±¼Àý¼ö¼ú, Ư¼öÄÜÅÃÆ®·»ÁîŬ¸®´ÐÀÌ´Ù. ƯÈ÷ ¿øÃß°¢¸·°ú ³Ä¡¼ºÀ±ºÎ°áÇÌÁúȯÀÚ¸¦ À§ÇÑ Àü¹® Ŭ¸®´ÐÀ» ¿î¿µÇϰí ÀÖ´Ù. ³Ä¡¼ºÀ±ºÎ°áÇÌÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ Àç»ýÀÇÇÐ ¿¬±¸¿Í °¢¸·±âÁõÀÇ ºÎÁ· Çö»óÀ» ÇØ°áÇϱâ À§ÇÑ ´ëüÀÇÇÐÀÎ ÀÌÁ¾À̽ÄÀ» ¿¬±¸Çϰí ÀÖ´Ù.
Á¦ ¸ñ | ±¼Àý±³Á¤¼ö¼ú 3ÆÇ | ||
---|---|---|---|
ÃâÆÇ»ç | ÃÖ½ÅÀÇÇлç | ¹ßÇàÀÏ | 2014 |
Á¦ ¸ñ | °¢¸· 3ÆÇ | ||
---|---|---|---|
ÃâÆÇ»ç | ÀÏÁ¶°¢ | ¹ßÇàÀÏ | 2013 |
Á¦ ¸ñ | Clinical Characteristics and Therapeutic Outcomes of Pediatric Blepharokeratoconjunctivitis | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2023-5 | ¹ßÇ¥Áö | CORNEA |
Á¦ ¸ñ | Clinical Characteristics and Therapeutic Outcomes of Pediatric Blepharokeratoconjunctivitis | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2022-8 | ¹ßÇ¥Áö | CORNEA |
Á¦ ¸ñ | Sutureless contact lens-type amniotic membrane for persistent epithelial defects after infectious keratitis | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2022-8 | ¹ßÇ¥Áö | INTERNATIONAL JOURNAL OF OPHTHALMOLOGY |
Á¦ ¸ñ | Clinical outcome of Descemet membrane endothelial keratoplasty (DMEK) with imported donor corneas in eyes of Asian patients; endothelium-in versus endothelium-out method | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2022-6 | ¹ßÇ¥Áö | PLOS ONE |
Á¦ ¸ñ | Matrix metalloproteinase 9 is associated with conjunctival microbiota culture positivity in Korean patients with chronic Stevens-Johnson syndrome | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2022-4 | ¹ßÇ¥Áö | BMC OPHTHALMOLOGY |
Á¦ ¸ñ | Proteomics Analysis of Aqueous Humor and Rejected Graft in Pig-to-Non-Human Primate Corneal Xenotransplantation | ||
---|---|---|---|
¹ßÇ¥³âµµ | Frontiers in Immunology ¹ßÇ¥³â¿ù 2022-3 | ¹ßÇ¥Áö | Frontiers in Immunology |
Á¦ ¸ñ | Clinical Outcomes in Maximum Tolerated Medical Therapy in Penetrating Keratoplasty for Bullous Keratopathy | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2022-3 | ¹ßÇ¥Áö | Áö Frontiers in Medicine |
¼¿ï´ëº´¿øÀº º»¿øÀ» ºñ·ÔÇÑ ¾î¸°À̺´¿ø, ¾Ïº´¿ø, ÀÇ»ý¸í¿¬±¸¿øÀ¸·Î ±¸¼ºµÅ ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î 1786º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 540¿© ¸íÀÇ ±³¼ö¿Í 5400¿© ¸íÀÇ Á÷¿øÀÌ ÇÏ·ç Æò±Õ 1700¿© ¸íÀÇ ÀÔ¿øÈ¯ÀÚ¿Í 8600¸íÀÌ ³Ñ´Â ¿Ü·¡È¯ÀÚ¸¦ µ¹º¸°í ÀÖ´Ù. ¼¼°èÀû ÷´Ü Áø·á ¿µ¿ªÀ» Áö¼ÓÀûÀ¸·Î È®º¸ÇÔÀ¸·Î½á ÃÖ»óÀÇ Áø·á ¼ºñ½º¸¦ Á¦°øÇϰí, ¿ì¸®³ª¶ó ÀÇ·á ¼±ÁøÈ¸¦ Ãß±¸ÇÏ´Â Á¤Ã¥ Çù·Â º´¿øÀÌ´Ù.
¼¿ïƯº°½Ã Á¾·Î±¸ ´ëÇзΠ101